PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Eptinezumab→

Eptinezumab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1644539-04-7
Molecular formula
Not reported
Molecular weight
Approximately 143,283 Da (18 disulfide bonds)
Drug class
Calcitonin gene-related peptide (CGRP) ligand inhibitorhumanised monoclonal antibody
Mechanism of action
Binds CGRP ligand and prevents its interaction with the CGRP receptor, inhibiting a pathway involved in migraine pathophysiology.
Indications / reported uses
  • Preventive treatment of migraine in adults; administered by intravenous infusion every three months under the product label, not for acute treatment of migraine attacks

Sources: US DailyMed — VYEPTI (eptinezumab-jjmr) · FDA prescribing information · FDA product information

Identification source: The FDA chemistry review reports a molecular weight of 143,283 Da for eptinezumab with 18 disulfide bonds. The review does not provide a single molecular formula.

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Eptinezumab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Eptinezumab Permitted Daily Exposure (PDE) report (the Eptinezumab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Eptinezumab Occupational Exposure Limit (OEL) report (the Eptinezumab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.